81 results on '"Edelman, A. J."'
Search Results
2. Benchmarks for Academic Oncology Faculty
3. New Therapies in Special Populations
4. Prophylactic Cranial Irradiation for Small-Cell Lung Cancer: Time for a Reassessment
5. Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers.
6. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).
7. A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.
8. First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
9. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer (CA) patients (pts) with and without human immunodeficiency virus (HIV) infection.
10. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.
11. Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456.
12. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
13. Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non–Small-Cell Lung Cancer
14. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
15. Prostaglandin E Receptor EP4 (EP4) expression, survival and pattern of recurrence in locally advanced NSCLC (LANSCLC).
16. PD-1, PD-L1, and B7-H3 expression in Human Immunodeficiency Virus (HIV) infected patients with aerodigestive (AD) cancers (CA).
17. Outcomes of patients (pts) with disease recurrence after treatment for locally advanced non-small cell lung cancer (LANSCLC) detected by routine follow-up (f/u) CT scans vs. symptom (sx) driven evaluation.
18. A phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate (SMDC) folate-tubulysin EC1456 in advanced cancer patients.
19. Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.
20. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.
21. Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies.
22. Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA).
23. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer
24. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.
25. A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
26. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
27. Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.
28. Stimulating an immune response through bavituximab in a phase III lung cancer study.
29. 50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
30. Results from a phase 2 trial of bortezomib (B) and sorafenib (S) in unresectable or metastatic renal cell cancer.
31. Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
32. Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status
33. Phase I and pharmacokinetic trial of the antitemolerase agent KML001 (KML) and cisplatin (CDDP) in advanced solid tumors.
34. A randomized, open-label phase II study of single-agent vintafolide versus vintafolide plus docetaxel versus docetaxel alone in second-line NSCLC patients with all target lesions expressing folate-receptor (TARGET).
35. Dose reduction (DR) due to chemotherapy induced peripheral neuropathy (CIPN) in breast cancer (BC) patients (pts) in the neoadjuvant/adjuvant settings.
36. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.
37. Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
38. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
39. Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer
40. A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression.
41. Sociodemographic and patient disparities in use of first-line chemotherapy (CT) in older adult patients (pts) with advanced non-small cell lung cancer (AdvNSCLC): Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare data.
42. A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.
43. Validation of a claims-based predicted performance status measure in SEER-Medicare.
44. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
45. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.
46. Increased circulating level of the autocrine growth factor GP88 (PC cell-derived growth factor factor/progranulin) in early- and advanced-stage non-small cell lung cancer and small cell lung cancer.
47. Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
48. A phase I study of ARRY-520 in solid tumors.
49. Development of a performance status prediction model for use in administrative data analyses.
50. RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.